Furthermore, this study reveals that RPS6KA2 enhances ferroptosis, indicating that modulation of ferroptosis represents an additional key mechanism by which RPS6KA2 regulates cisplatin sensitivity in ovarian cancer cells. Here, RPS6KA2 is linked to ovarian carcinoma.